カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の筋弛緩剤市場2023-2030：薬剤種類別（骨格筋弛緩剤、顔面筋弛緩剤）、投与経路別、流通チャネル別、地域別

【英語タイトル】Muscle Relaxant Drugs Market Size, Share & Trends Analysis Report By Drug Type (Skeletal Muscle Relaxant Drugs, Facial Muscle Relaxant Drugs), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23JUN075）・商品コード：GRV23JUN075
・発行会社（調査会社）：Grand View Research
・発行日：2023年5月10日
・ページ数：180
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Grand View Research社の市場調査書によると、世界の筋弛緩剤市場規模が、予測期間中（2023年～2030年）に年平均4.38％増加し、2030年までに52.8億ドルへ達すると見込まれています。本調査書では、筋弛緩剤の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、薬剤種類別（骨格筋弛緩剤、顔面筋弛緩剤、神経筋遮断薬）分析、投与経路別（経口、注射、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋中南米、中東・アフリカ）分析、競争状況などについて調査・分析し、まとめています。なお、こちらに掲載されている企業情報には、Amneal Pharmaceuticals LLC、Ipsen Biopharmaceuticals, Inc.、Merz Pharmaceuticals, LLC.、Par Pharmaceutical、Endo Pharmaceuticals、Vertical Pharmaceuticals、Mallinckrodt、SteriMax、Eisai Co., Ltd.、Teva Pharmaceuticals USA, Inc.などが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・世界筋弛緩剤の市場規模：薬剤種類別
- 骨格筋弛緩剤の市場規模
- 顔面筋弛緩剤の市場規模
- 神経筋遮断薬の市場規模
・世界筋弛緩剤の市場規模：投与経路別
- 経口における市場規模
- 注射における市場規模
- その他投与経路における市場規模
・世界筋弛緩剤の市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界筋弛緩剤の市場規模：地域別
- 北米の筋弛緩剤市場規模
- ヨーロッパの筋弛緩剤市場規模
- アジア太平洋の筋弛緩剤市場規模
- 中南米の筋弛緩剤市場規模
- 中東・アフリカの筋弛緩剤市場規模
・競争状況

筋弛緩剤市場の成長と動向

Grand View Research社の最新レポートによると、世界の筋弛緩剤市場規模は2030年までに52億8000万米ドルに達する見込みです。2023年から2030年までのCAGRは4.38%で市場は拡大する見込みです。同市場では、筋肉の痙縮や痙攣を治療するための弛緩剤の使用が増加しています。これは、筋骨格系障害を持つ高齢者人口の増加、外科手術の件数の増加、腰痛につながる座りっぱなしのライフスタイル、仕事に関連した筋骨格系障害、及びこのような薬剤の需要増加につながるその他の要因に起因しています。例えば、Elsevierの論文によると、2021年12月の調査では、医療従事者の64.0％が業務に関連した筋骨格系疾患を有しており、腰痛が最も頻度の高い訴えでしました。したがって、このような疾患の有病率の上昇は、筋弛緩剤市場に有利な成長機会を提供します。

この市場には、腰痛を管理するための多様な薬剤が存在します。これらには、痙縮を治療するためのバクロフェン、チザニジン、ダントロレンの3つのFDA承認薬と、筋痙攣を治療するためのカリソプロドール、メタキサロン、メトカルバモール、クロルゾキサゾン、オルフェナドリン、シクロベンザプリンの6つのFDA承認薬が含まれます。ボツリヌス毒素も痙縮の治療薬として承認されていますが、特定の症例にのみ使用されています。

市場の主要プレーヤーは、新しい治療法を開発し、新製品やジェネリック医薬品を市場に投入しています。例えば、2021年7月、Hikma Pharmaceuticals Plc社は、手術や人工呼吸に伴う骨格筋弛緩を適応症とする20mg/mlサクシニルコリン塩化物注射液を米国で発売すると発表しました。このような神経筋遮断剤（例：サクシニルコリン、ドキサクリウム、シサトラクリウム、ロクロニウム）は手術中に重要な役割を担います。2022年1月、Amneal Pharmaceuticals社はSaolのBaclofenフランチャイズの買収を発表し、同セグメントのリオレサール、ライビスパー、臨床用製品で同社の製品ポートフォリオを増強しました。

しかし、筋弛緩剤に伴う副作用が市場の成長を妨げる可能性があります。例えば、2021年、Sandoz社は経口オルフェナドリンクエン酸塩100mg徐放錠13ロットをリコールしました。検査中に基準値を超えるニトロソアミンが確認されたためで、このニトロソアミンは癌につながる可能性があります。

筋弛緩剤市場レポートハイライト

– 薬剤タイプ別では、骨格筋弛緩剤セグメントが2022年に約36.54%の最大シェアを占めました。これは、筋骨格系の問題の有病率の増加と、その治療と管理に対する顧客の意識の高まりによるものです。

– 投与経路別では、経口剤が世界市場で大きなシェアを占めています。経口剤での筋弛緩剤の使用は、経口剤での製品の入手可能性の高さと処方率の高さにより急増しています。

– 流通チャネル別では、病院薬局セグメントが2022年に46.76%のシェアを占めました。

– 北米は、製薬業界の成長、高い研究開発投資の存在、同地域における新規筋弛緩剤製品の開発により、2022年の世界市場を席巻しました。

– アジア太平洋地域は、ジェネリック産業の隆盛と、同地域での存在感を高めるための大手市場参入企業による投資の増加により、今後大幅な成長が見込まれます。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Growing geriatric population
3.4.2. Increasing prevalence of musculoskeletal disorders
3.5. Market Restraint Analysis
3.5.1. Adverse effects of muscle relaxants
3.6. Penetration and Growth Prospect Mapping 2022
3.7. Business Environment Analysis
3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. COVID – 19 Impact Analysis
Chapter 4. Drug Type Business Analysis
4.1. Muscle relaxant drugs market: Drug Type Movement Analysis
4.2. Skeletal Muscle Relaxant Drugs
4.2.1. Skeletal Muscle Relaxant Market, 2018 – 2030 (USD Million)
4.3. Facial Muscle Relaxant Drugs
4.3.1. Facial Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
4.4. Neuromuscular Blocking Agents
4.4.1. Neuromuscular Blocking Agents Market, 2018 – 2030 (USD Million)
Chapter 5. Route of Administration Business Analysis
5.1. Muscle relaxant drugs market: Route of Administration Movement Analysis
5.2. Oral Market, 2018 – 2030 (USD Million)
5.2.1. Oral Market, 2018 – 2030 (USD Million)
5.3. Injectable
5.3.1. Injectable Market, 2018 – 2030 (USD Million)
5.4. Others
5.4.1. Others Market ,2018 – 2030 (USD Million)
Chapter 6. Distribution Channel Business Analysis
6.1. Muscle relaxant drugs market: Distribution Channel Movement Analysis
6.2. Hospital Pharmacy
6.2.1. Hospital Pharmacy Market, 2018 – 2030 (USD Million)
6.3. Retail Pharmacy
6.3.1. Retail Pharmacy Market, 2018 – 2030 (USD Million)
6.4. Online Pharmacy
6.4.1. Online Pharmacy Market, 2018 – 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Muscle Relaxant Drugs Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.2.3. U.S.
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Reimbursement Scenario
7.2.3.6. U.S. Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.2.4. Canada
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Reimbursement Scenario
7.2.4.6. Canada Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.3. Europe
7.3.1. SWOT Analysis
7.3.2. Europe Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Reimbursement Scenario
7.3.3.6. Germany Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.3.4. UK
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Reimbursement Scenario
7.3.4.6. UK Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Scenario
7.3.5.6. France Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Scenario
7.3.6.6. Italy Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.3.7. Spain
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Scenario
7.3.7.6. Spain Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.3.8. Denmark
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Scenario
7.3.8.6. Denmark Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.3.9. Sweden
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Scenario
7.3.9.6. Sweden Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.3.10. Norway
7.3.10.1. Key Country Dynamics
7.3.10.2. Target Disease Prevalence
7.3.10.3. Competitive Scenario
7.3.10.4. Regulatory Framework
7.3.10.5. Reimbursement Scenario
7.3.10.6. Norway Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.4. Asia Pacific
7.4.1. SWOT Analysis
7.4.2. Asia Pacific Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Reimbursement Scenario
7.4.3.6. Japan Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.4.4. China
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. Reimbursement Scenario
7.4.4.6. China Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.4.5. India
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Scenario
7.4.5.6. India Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.4.6. South Korea
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Scenario
7.4.6.6. South Korea Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.4.7. Australia
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Scenario
7.4.7.6. Australia Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.4.8. Thailand
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. Reimbursement Scenario
7.4.8.6. Thailand Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.5. Latin America
7.5.1. SWOT Analysis
7.5.2. Latin America Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.5.3. Brazil
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Reimbursement Scenario
7.5.3.6. Brazil Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.5.4. Mexico
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Reimbursement Scenario
7.5.4.6. Mexico Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.5.5. Argentina
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Competitive Scenario
7.5.5.4. Regulatory Framework
7.5.5.5. Reimbursement Scenario
7.5.5.6. Argentina Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.6. MEA
7.6.1. SWOT Analysis
7.6.2. MEA Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.6.3. South Africa
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Reimbursement Scenario
7.6.3.6. South Africa Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.6.4. Saudi Arabia
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Reimbursement Scenario
7.6.4.6. Saudi Arabia Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.6.5. UAE
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Scenario
7.6.5.6. UAE Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
7.6.6. Kuwait
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Competitive Scenario
7.6.6.4. Regulatory Framework
7.6.6.5. Reimbursement Scenario
7.6.6.6. Kuwait Muscle Relaxant Drugs Market, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. Amneal Pharmaceuticals LLC
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Ipsen Biopharmaceuticals, Inc.
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Merz Pharmaceuticals, LLC.
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Par Pharmaceutical
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Endo Pharmaceuticals
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Vertical Pharmaceuticals
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Mallinckrodt
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. SteriMax
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Eisai Co., Ltd.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Teva Pharmaceuticals USA, Inc.
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives

List of Tables

Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 4. Global muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 5. Global muscle relaxant drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 6. Global muscle relaxant drugs market, by region, 2018 - 2030 (USD Million)
Table 7. North America muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 8. North America muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 9. North America muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 10. North America muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 11. U.S. muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 12. U.S. muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 13. U.S. muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 14. Canada muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 15. Canada muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 16. Canada muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 17. Europe muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 18. Europe muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 19. Europe muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 20. Europe muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 21. UK muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 22. UK muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 23. UK muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 24. Germany muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 25. Germany muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 26. Germany muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 27. France muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 28. France muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 29. France muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 30. Italy muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 31. Italy muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 32. Italy muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 33. Spain muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 34. Spain muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 35. Spain muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 36. Denmark muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 37. Denmark muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 38. Denmark muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 39. Sweden muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 40. Sweden muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 41. Sweden muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 42. Norway muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 43. Norway muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 44. Norway muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 45. Asia Pacific muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 46. Asia Pacific muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 47. Asia Pacific muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 48. Asia pacific muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 49. China muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 50. China muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 51. China muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 52. India muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 53. India muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 54. India muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 55. Japan muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 56. Japan muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 57. Japan muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 58. Thailand muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 59. Thailand muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 60. Thailand muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 61. Australia muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 62. Australia muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 63. Australia muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 64. South Korea muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 65. South Korea muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 66. South Korea muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 67. Latin America muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 68. Latin America muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 69. Latin America muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 70. Latin America muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 71. Brazil muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 72. Brazil muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 73. Brazil muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 74. Mexico muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 75. Mexico muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 76. Mexico muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 77. Argentina muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 78. Argentina muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 79. Argentina muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 80. Middle East & Africa muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 81. Middle East & Africa muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 82. Middle East & Africa muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 83. Middle East & Africa muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 84. South Africa muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 85. South Africa muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 86. South Africa muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 87. Saudi Arabia muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 88. Saudi Arabia muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 89. Saudi Arabia muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 90. UAE muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 91. UAE muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 92. UAE muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 93. Kuwait muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 94. Kuwait muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 95. Kuwait muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)

★調査レポート[世界の筋弛緩剤市場2023-2030：薬剤種類別（骨格筋弛緩剤、顔面筋弛緩剤）、投与経路別、流通チャネル別、地域別] (コード：GRV23JUN075)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の筋弛緩剤市場2023-2030：薬剤種類別（骨格筋弛緩剤、顔面筋弛緩剤）、投与経路別、流通チャネル別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の降圧薬市場2024-2030：薬剤クラス別（利尿薬、ACE阻害薬）、種類別（一次、二次）、投与経路別、流通チャネル別、地域別
  • 世界の解毒薬市場2024-2030：種類別（化学的解毒剤、物理的解毒剤、薬理学的解毒剤）、投与経路別、流通チャネル別、エンドユーザー別、地域別
  • 世界のピーナッツアレルギー治療市場2023-2030：薬物クラス別（抗ヒスタミン薬、エピネフリン）、投与経路別、流通チャネル別、地域別
  • 世界のピーナッツアレルギー治療薬市場2024-2030：薬剤クラス別（抗ヒスタミン薬、エピネフリン）、投与経路別、流通チャネル別、地域別
  • 世界のブランドジェネリック市場2023-2030：薬物クラス別（アルキル化剤、代謝拮抗剤、抗高血圧剤）、用途別、投与経路別、流通チャネル別、地域別
  • 世界のワクチン市場2023-2030：種類別（サブユニット、mRNA）、投与経路別（経口、経鼻）、疾患別（HPV、MMR）、年齢層別、流通チャネル別
  • 世界のジェネリック医薬品市場2023-2030：種類別（一般ジェネリック、特殊ジェネリック、バイオシミラー）、投与経路別、製品別、用途別、流通チャネル別、地域別
  • 世界の炎症性腸疾患（IBD）治療市場2023-2030：種類別（クローン病、潰瘍性大腸炎）、薬剤クラス別、投与経路別、流通チャネル別、地域別
  • 世界のインフルエンザ治療薬市場2024-2030：治療薬別（ペラミビル、ザナミビル、バロキサビル マルボキシル、リン酸オセルタミビル）、投与経路別、流通チャネル別、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆